Discovery of effect predictor of anti-PD-1 antibody in lung cancer

2017 Fiscal Year Final Research Report

• Project/Area Number: 16K18455
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Tumor therapeutics
• Research Institution: Nagasaki University
• Principal Investigator: IKEDA Takaya 長崎大学, 病院(医学系), 助教 (00773871)
• Research Collaborator: OHYAMA Kaname 長崎大学, 医歯薬学総合研究科(薬学系), 准教授 (50437860) ; NAKAMURA Yoichi 栃木県立がんセンター, 呼吸器内科, 医長 (20432974)
• Project Period (FY): 2016-04-01 – 2018-03-31
• Keywords: 肺がん / 免疫チェックポイント阻害剤 / 抗PD-1抗体 / ニボルマブ / 効果予測因子 / イムノコンプレキソーム法

Outline of Final Research Achievements

There were 25 cases of case registration. The median age was 68 years, 19 males and 6 females. Tissue types were 16 adenocarcinomas, 7 squamous cell carcinomas and 2 large cell carcinomas. Stage classification was 3 cases in stage III, 19 cases in stage IV and 3 cases after surgery. There were 21 cases of smoking history. Response was obtained in 6 of 25 patients treated with nivolumab and the response rate was 24.0%, median progression-free survival was 107 days. Analysis of antigen protein by Immune Complexome Analysis on 25 subjects revealed specific antigenic proteins only in 6 responding cases. Patients expressing these antigenic proteins may have a response to nivolumab, which may be a predictive factor for the effect of nivolumab.

Free Research Field

呼吸器腫瘍学